Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
September 18 2024 - 5:00PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a
clinical stage biopharmaceutical company focused on improving
patient outcomes through best-in-class therapies for liver and
viral diseases, today announced that the Company will share the
topline results from the Phase 2a HERALD study of ALG-055009, a
thyroid hormone receptor beta (THR-β) agonist, in
metabolic-dysfunction associated steatohepatitis (MASH) subjects on
Thursday, September 19, 2024 prior to the market open. Following
the announcement, the Company will host a conference call and
webcast at 8:30am ET/5:30am PT.
Conference Call & Webcast Details
The company will host a conference call and webcast with a slide
presentation tomorrow at 8:30am ET/5:30am PT. To access the live
webcast with slides, please visit the Presentation & Events
page on the Aligos website at www.aligos.com. Please register ten
minutes prior to its start. Following the live webcast, a replay
will be available on the company’s website for 90 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage
biopharmaceutical company founded with the mission to improve
patient outcomes by developing best-in-class therapies for the
treatment of liver and viral diseases. Aligos applies its science
driven approach and deep R&D expertise to advance its
purpose-built pipeline of therapeutics for metabolic
dysfunction-associated steatohepatitis (MASH) and viruses with high
unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us
on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements,” including
without limitation, statements regarding Aligos’ financial results
and performance as well as research and development activities,
including regulatory status and the timing of announcements and
updates relating to our regulatory filings and clinical trials.
Such forward looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, and
other matters that could affect the sufficiency of Aligos’ capital
resources to fund operations. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 6, 2024 and its future periodic
reports to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
Investor ContactAligos Therapeutics, Inc.Jordyn
TaraziVice President, Investor Relations & Corporate
Communications+1 (650) 910-0427jtarazi@aligos.com
Media ContactInizio EvokeJake RobisonVice
PresidentJake.Robison@inzioevoke.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Nov 2023 to Nov 2024